IRS2 and breast carcinoma: The association of IRS-2 with tumor progression was first indicated by the finding that inhibition of the IGF-1R in ER- breast carcinoma cells, which express IRS-2 and lack or have decreased IRS-1 expression, does not inhibit tumor proliferation.